OKYO Pharma (OKYO)
Develops urcosimod eye drops for neuropathic corneal pain and anterior-segment eye diseases.
$1.34
vs last close−0.01 (−1.11%)
Something off on this page? Send us feedback.
Next report
Dec 2, 26
estimated · in 70 days
EPS estimate
−$0.06
Revenue estimate
—
Fiscal quarter
Q2 FY27
EPSReportedEstimate
May '24Oct '24Jan '25Jul '25Jan '26Jun '26Jul '26Dec '26
Reported−$0.30−$0.08−$0.08−$0.04−$0.01−$0.04−$0.15Pending
Estimate———−$0.05−$0.07−$0.08−$0.08−$0.06
Surprise———+19.6%+85.7%+49.8%−87.5%—
RevenueReportedEstimate
May '24Oct '24Jan '25Jul '25Jan '26Jun '26Jul '26Dec '26
Reported———————Pending
Estimate————————
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$0.06 | — | — |
| Aug 2026 | — | — | — |
| Jul 2026 | −$0.08 | −$0.15 | −87.5% |
| Jun 2026 | −$0.08 | −$0.04 | +49.8% |
| Jan 2026 | −$0.07 | −$0.01 | +85.7% |
| Jul 2025 | −$0.05 | −$0.04 | +19.6% |
| Jan 2025 | |||
| Oct 2024 | |||
| Aug 2024 | — | — | — |
| May 2024 | |||
| Jan 2024 | — | — | — |
| Nov 2023 | |||
| Oct 2023 | |||
| Aug 2023 | — | — | — |
| Mar 2023 | |||
| Dec 2022 | — | — | — |
| Oct 2022 | |||
| Mar 2022 | |||
| Sep 2021 | |||
| Mar 2021 | |||
| Sep 2020 | |||
| Mar 2020 | |||
| Sep 2019 | |||
| Mar 2019 | |||
| Sep 2018 | |||
| Mar 2018 | |||
| Sep 2017 | |||
| Mar 2017 | |||
| Sep 2016 | |||
| Mar 2016 | |||
| Sep 2015 | |||
| Mar 2015 | |||
| Sep 2014 | |||
| Mar 2014 | |||
| Sep 2013 | |||
| Mar 2013 | |||
| Sep 2012 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2, 2026 | −$0.06 | — | — | $0 | — | — | — |
| Aug 10, 2026 | — | — | — | — | — | — | — |
| Jul 20, 2026 | −$0.08 | −$0.15 | −87.5% | — | — | — | −4.2% |
| Jun 3, 2026 | −$0.08 | −$0.04 | +49.8% | — | — | — | +1.2% |
| Jan 30, 2026 | −$0.07 | −$0.01 | +85.7% | — | — | — | +2.0% |
| Jul 18, 2025 | −$0.05 | −$0.04 | +19.6% | — | — | — | +3.1% |
| Jan 29, 2025 | |||||||
| Oct 2, 2024 | |||||||
| Aug 13, 2024 | — | — | — | — | — | — | — |
| May 13, 2024 | |||||||
| Jan 9, 2024 | — | — | — | — | — | — | — |
| Nov 29, 2023 | |||||||
| Oct 1, 2023 | |||||||
| Aug 15, 2023 | — | — | — | — | — | — | — |
| Mar 31, 2023 | |||||||
| Dec 30, 2022 | — | — | — | — | — | — | — |
| Oct 1, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Sep 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Sep 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Sep 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Sep 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Sep 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Sep 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Sep 30, 2015 | |||||||
| Mar 31, 2015 | |||||||
| Sep 30, 2014 | |||||||
| Mar 31, 2014 | |||||||
| Sep 30, 2013 | |||||||
| Mar 31, 2013 | |||||||
| Sep 30, 2012 |